Compare · NUS vs PETQ
NUS vs PETQ
Side-by-side comparison of Nu Skin Enterprises Inc. (NUS) and PetIQ Inc. (PETQ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NUS and PETQ operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- PETQ is the larger of the two at $570.2M, about 2.2x NUS ($260.7M).
- NUS has hit the wire 10 times in the past 4 weeks while PETQ has been quiet.
- PETQ has more recent analyst coverage (8 ratings vs 4 for NUS).
- Company
- Nu Skin Enterprises Inc.
- PetIQ Inc.
- Price
- $5.31-1.21%
- $30.99+0.02%
- Market cap
- $260.7M
- $570.2M
- 1M return
- -24.36%
- -
- 1Y return
- -33.87%
- -
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- 1996
- 2017
- News (4w)
- 10
- 0
- Recent ratings
- 4
- 8
Nu Skin Enterprises Inc.
Nu Skin Enterprises, Inc. develops and distributes personal care and wellness products worldwide. It provides skin care systems, including ageLOC Me customized skin care and ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products comprising botanical ingredients derived from renewable sources, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, and LifePak nutritional supplements, as well as other anti-aging nutritional solutions and weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
PetIQ Inc.
PetIQ, Inc. operates as a pet medication and wellness company. It operates in two segments, Products and Services. The company offers Rx pet medications, which include heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and co-develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at community clinics and wellness centers hosted at pet retailers across 41 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It operates through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.
Latest NUS
- Director Winett James M was granted 26,643 shares and sold $40,481 worth of shares (7,203 units at $5.62) as part of a pre-agreed trading plan, increasing direct ownership by 108% to 37,448 units (SEC Form 4)
- Director Nathanson Laura was granted 26,643 shares, increasing direct ownership by 87% to 57,116 units (SEC Form 4)
- Director Zorko Mark A was granted 26,643 shares, increasing direct ownership by 78% to 60,586 units (SEC Form 4)
- Director Woodbury Edwina D was granted 26,643 shares and sold $41,057 worth of shares (7,203 units at $5.70) as part of a pre-agreed trading plan, increasing direct ownership by 45% to 62,433 units (SEC Form 4)
- Director Battle Emma S. was granted 26,643 shares, increasing direct ownership by 86% to 57,648 units (SEC Form 4)
- Director Thomas Pisano R. was granted 26,643 shares, increasing direct ownership by 30% to 116,827 units (SEC Form 4)
- Director Campbell Daniel W was granted 26,643 shares, increasing direct ownership by 68% to 65,859 units (SEC Form 4)
- SEC Form S-8 filed by Nu Skin Enterprises Inc.
- Nu Skin Enterprises Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form SD filed by Nu Skin Enterprises Inc.
Latest PETQ
- PetIQ Names Camillo Pane as Chief Executive Officer
- Amendment: SEC Form SC 13G/A filed by PetIQ Inc.
- Amendment: SEC Form SC 13G/A filed by PetIQ Inc.
- SEC Form 15-12G filed by PetIQ Inc.
- Amendment: SEC Form SC 13G/A filed by PetIQ Inc.
- Amendment: SEC Form SC 13G/A filed by PetIQ Inc.
- Chief Financial Officer Glasman Zvi returned 25,800 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Huff Scott returned 6,077 shares to the company, closing all direct ownership in the company (SEC Form 4)
- EVP Manufacturing & Sup. Chain Lyon Chad D. returned 10,659 shares to the company, closing all direct ownership in the company (SEC Form 4)
- EVP, GENERAL COUNSEL Carter William J. returned 3,497 shares to the company, closing all direct ownership in the company (SEC Form 4)